The S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.05%....
The S&P 500 Index ($SPX ) (SPY ) is down by -0.02% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.10%. E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) is up by +0.04% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.01%. E-mini S&P futures (ESU26...
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III...
First Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Benefit in a Global Phase III Study of EGFR-Mutated NSCLC after Third-Generation EGFR TKI Progression ...
Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China ...
HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC ...
NEW YORK , July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT)...
Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy ...
Barchart Research What to Expect from SMMT Earnings SMMT Generated July 22, 2026 Current Price $14.74 EPS Estimate $$-0.26 Consensus Rating Moderate Buy Average Move 7.42% Summit Therapeutics: The Conference...